Melatonin: Dosage, Safety, Side Effects, and How It Compares to Prescription Sleep Aids

What Is Melatonin and How Does It Work?

Melatonin is an endogenous indoleamine produced by the pineal gland in response to darkness. It binds MT1 and MT2 receptors in the suprachiasmatic nucleus to phase-shift the circadian clock and reduce core body temperature, creating the physiological conditions that allow sleep to begin. Production peaks between 2 AM and 4 AM in most adults and is almost entirely suppressed by light exposure, particularly blue-spectrum light in the 460, 480 nm range.

Exogenous melatonin does not knock you unconscious the way a GABA-A agonist does. It shifts the timing of sleep rather than forcing it. That distinction matters clinically. A 2017 Cochrane review of melatonin for jet lag (Herxheimer 2002, updated) concluded that melatonin is "remarkably effective" at preventing or reducing jet lag when taken close to target bedtime at the destination, particularly for eastward travel crossing five or more time zones.

Serum melatonin rises within 30 minutes of a 0.5 mg oral dose and reaches pharmacological levels comparable to endogenous nighttime peaks. Doses of 10 mg (common in US drugstores) produce blood levels 10, 100 times higher than physiological and prolong morning sedation without improving sleep-onset latency further. A randomized crossover trial by Vondrasova and colleagues published in Physiological Research found that 0.3 mg and 1 mg doses performed at least as well as 3 mg for phase advancement, with less next-day grogginess.

What Dose of Melatonin Should You Take?

Most adults need 0.5 to 3 mg. Doses above 3 mg rarely improve outcomes and increase side-effect burden.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline on the pharmacologic treatment of chronic insomnia states: "We suggest that clinicians use melatonin for sleep onset insomnia (versus no treatment)" at the lowest effective dose, while cautioning that evidence quality is low. For jet lag specifically, the guideline supports 0.5 to 3 mg taken at destination bedtime.

Timing is as important as dose. Taking melatonin at the wrong circadian phase can actually delay sleep rather than advance it. The optimal window is 30 to 60 minutes before your intended sleep time when you are already in a dim-light environment. For eastward jet lag, take it at destination bedtime starting the night of travel. For westward jet lag, take it at destination bedtime for the first two to three nights only.

Extended-release formulations (e.g., Circadin 2 mg, prescription in Europe) mimic the slow overnight rise of endogenous melatonin and show modest benefit for sleep maintenance in adults over 55, where natural melatonin production declines. A 26-week randomized trial published in Current Medical Research and Opinion (N=354) found prolonged-release melatonin 2 mg improved sleep quality scores and next-morning alertness compared to placebo without rebound insomnia on discontinuation.

Melatonin Side Effects and Safety Profile

Melatonin has an unusually clean safety record at doses <3 mg. No lethal dose has been established in humans.

Reported adverse effects at therapeutic doses include:

• Daytime drowsiness (most common, dose-dependent)
• Headache (reported in roughly 8% of users in pooled data)
• Dizziness and mild nausea at doses >5 mg
• Hypothermia at very high doses (>50 mg) studied in pharmacokinetic research

Melatonin interacts meaningfully with warfarin (may potentiate anticoagulant effect), fluvoxamine (dramatically raises melatonin plasma levels via CYP1A2 inhibition), and benzodiazepines (additive sedation). Patients on any of those drugs should consult a physician before supplementing.

Chronic high-dose use in adolescents raises theoretical concern about pubertal timing because melatonin suppresses gonadotropin-releasing hormone in some animal models. Human data are insufficient to draw firm conclusions. A 2023 JAMA Pediatrics analysis of poison-control data reported a 530% increase in pediatric melatonin ingestion calls between 2012 and 2021, with most cases involving unsupervised access to adult products. Keep all sleep supplements out of reach of children.

Melatonin vs. Zolpidem (Ambien): When Prescription Z-Drugs Are Appropriate

Zolpidem is a non-benzodiazepine GABA-A positive allosteric modulator approved by the FDA for short-term treatment of sleep-onset insomnia. It is faster and more powerful than melatonin for acute insomnia but carries real risks melatonin does not.

The FDA revised zolpidem dosing guidance in 2013 after data showed that standard 10 mg doses left women with next-morning blood concentrations above the 50 ng/mL threshold associated with impaired driving. Current recommended doses are 5 mg (women) and 5 to 10 mg (men) for immediate-release formulations, taken immediately before bed with at least 7 to 8 hours remaining before driving.

Dependence, tolerance, and rebound insomnia emerge with use beyond 7 to 10 days. Zolpidem also carries a boxed warning for complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating) that have caused serious injuries. For patients with chronic insomnia disorder, cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment per AASM guidelines, not zolpidem.

Melatonin is the better choice for jet lag, shift-work schedule adjustment, or mild sleep-onset difficulty without a formal insomnia diagnosis. Zolpidem is appropriate for short-term (7 to 10 day) management of acute insomnia when CBT-I is unavailable and daytime impairment is significant.

Eszopiclone (Lunesta) and Zaleplon (Sonata): Key Differences

Eszopiclone is the S-enantiomer of zopiclone, approved for both sleep onset and sleep maintenance. Unlike zolpidem, eszopiclone holds an FDA indication without a specific night-use duration limit, though the agency required the manufacturer to reduce the starting dose from 2 mg to 1 mg in 2014 after next-day impairment data emerged. A 6-month randomized trial published in Sleep (N=788) showed eszopiclone 3 mg significantly improved sleep latency, total sleep time, and daytime function versus placebo throughout the entire study period, the longest controlled hypnotic trial at the time of publication.

Zaleplon has the shortest half-life of the three Z-drugs, roughly one hour, which makes it uniquely suited to middle-of-the-night awakenings. A patient who wakes at 3 AM and has at least four hours remaining before they need to be alert can take zaleplon 10 mg with minimal residual sedation. Neither eszopiclone nor zolpidem can make that claim.

Melatonin does not compete with these drugs for acute insomnia. The sedative magnitude simply differs. Zaleplon at 10 mg reduces sleep-onset latency by approximately 15 to 20 minutes in clinical trials; melatonin at 0.5 to 3 mg reduces it by roughly 7 to 12 minutes in meta-analytic estimates from a 2013 PLOS ONE meta-analysis (13 trials, N=1,683).

Suvorexant (Belsomra): A Mechanistically Different Option

Suvorexant works by blocking orexin-1 and orexin-2 receptors, quieting the wake-promoting signals the brain sends rather than activating inhibitory GABA pathways. The FDA approved it in 2014 for sleep-onset and sleep-maintenance insomnia. DEA Schedule IV.

In the phase 3 SUVOREXANT trial published in The Lancet Neurology (N=1 to 021 in one arm; total program N over 3,000), suvorexant 20 mg reduced subjective sleep-onset latency by 10 minutes and wake time after sleep onset by 28 minutes versus placebo at 3 months. The effect was maintained at 12 months without dose escalation, which is a meaningful distinction from Z-drugs.

Next-day somnolence affected about 7% of patients on suvorexant 20 mg versus 3% on placebo. The drug carries a warning for worsening depression and suicidal ideation, same as most prescription sleep aids. Complex sleep behaviors were reported at lower rates than with Z-drugs in postmarketing surveillance, though the comparison is not randomized.

Melatonin and suvorexant target different biology and are not direct substitutes. A patient with true insomnia disorder may not respond to melatonin at all. Suvorexant is a reasonable first-prescription option for clinicians who want to avoid GABA-A modulation, particularly in patients with a history of substance use disorder.

Ramelteon: The Prescription Melatonin Receptor Agonist

Ramelteon (Rozerem, 8 mg) is the only FDA-approved prescription sleep aid with the same mechanism as melatonin. It binds MT1 and MT2 receptors with roughly 6-fold higher affinity than melatonin itself and has a half-life of 1 to 2.6 hours (active metabolite M-II extends to 2 to 5 hours).

Because ramelteon has no activity at GABA, histamine, or dopamine receptors, it carries no DEA scheduling and no boxed warning for complex sleep behaviors. A placebo-controlled trial in adults with chronic insomnia published in Sleep Medicine (N=829) showed ramelteon 8 mg reduced sleep-onset latency by a mean of 4 minutes versus placebo over 5 weeks, measured by polysomnography. That effect size is modest, similar to melatonin meta-analyses, but the drug's consistency and the absence of tolerance make it a reasonable long-term option for sleep-onset difficulty without maintenance problems.

Fluvoxamine raises ramelteon plasma levels roughly 190-fold via CYP1A2 and CYP3A4 inhibition. That combination is contraindicated. Patients on CYP1A2 inhibitors (ciprofloxacin, enoxacin) should also avoid ramelteon.

Melatonin for Special Populations

Older adults. Endogenous melatonin declines with age, partly because of pineal gland calcification. Adults over 65 often benefit from low-dose supplementation (0.5 to 1 mg) for sleep-onset difficulty. The 2019 American Geriatrics Society Beers Criteria recommends avoiding most prescription sleep aids (benzodiazepines, Z-drugs) in older adults due to fall and cognitive impairment risk. Melatonin is not on the Beers list.

Pregnant and breastfeeding patients. No controlled trial data support melatonin supplementation during pregnancy. Endogenous melatonin crosses the placenta and plays a role in fetal circadian development. Supplemental use during pregnancy should wait for physician guidance.

Shift workers. A 2014 Cochrane review of melatonin for shift-work sleep disorder found evidence suggesting it may increase daytime sleep length by about 24 minutes after night shifts, though evidence quality was rated as low. Timed light therapy plus melatonin outperforms melatonin alone for shift-work adaptation.

Children with neurodevelopmental conditions. Melatonin is widely used off-label for insomnia in children with autism spectrum disorder and ADHD. A randomized trial published in JAMA Pediatrics (Gringras et al., 2012) (N=146) found melatonin 0.5 to 12 mg improved sleep onset by 34.5 minutes versus 13.3 minutes for placebo (P<0.001) in children with neurodevelopmental disabilities. Long-term pubertal effects remain unstudied in this population.

How to Choose Between Melatonin and a Prescription Sleep Aid

The decision comes down to diagnosis. Melatonin addresses circadian timing problems. Prescription hypnotics address neurological hyperarousal, the kind that keeps people wide awake regardless of circadian phase.

Use melatonin first if the problem is:

• Jet lag (eastward travel across 5+ time zones)
• Delayed sleep-phase syndrome
• Shift-work schedule change
• Mild, occasional sleep-onset difficulty with no daytime impairment diagnosis

Consider a physician consultation for a prescription if the problem is:

• Chronic insomnia disorder (difficulty 3+ nights per week for 3+ months)
• Sleep maintenance failure (waking and unable to return to sleep)
• Significant daytime impairment affecting work or safety
• Failed trial of CBT-I plus melatonin

The AASM 2021 guideline on behavioral and psychological treatments for insomnia states: "We recommend multicomponent CBT-I as the initial treatment for chronic insomnia disorder in adults." Pharmacotherapy is an adjunct, not a replacement, for that standard.

Patients who cannot access CBT-I immediately (therapist waitlists commonly exceed 6 to 12 weeks) may use short-course zolpidem or suvorexant as a bridge, with a planned taper. Melatonin has no taper requirement and can be stopped abruptly.

Quality and Labeling Problems With OTC Melatonin in the United States

Because melatonin is sold as a dietary supplement rather than a drug in the US, it is not subject to FDA pre-market approval. A widely cited 2017 study in the Journal of Clinical Sleep Medicine (Cohen et al., N=31 commercially available products) found that actual melatonin content ranged from 83% below to 478% above the labeled dose. Ten percent of products also contained serotonin, an undisclosed active compound. Lot-to-lot variability within the same brand reached 465%.

Practical guidance: look for products carrying USP, NSF International, or ConsumerLab verification seals, which require third-party analytical testing. Start with the lowest available dose (0.5 mg or 1 mg) and titrate. Liquid drops allow sub-milligram dosing that gummies and tablets rarely provide.